The Association for Frontotemporal Degeneration

FTD is caused by
degeneration of the frontal
and/or temporal lobes of the brain.

It's the most common form of dementia for people under 60.

What is FTD?

Learn More

Download a Diagnostic Checklist

You don't have to take
this journey alone.

AFTD offers reliable information, resources,
and support for families facing FTD.

Find Support Managing FTD Newly Diagnosed

Bruce Willis & FTD

The Willis' Unexpected Journey

Initial Family Statement

Read about Emma Heming Willis' book tour

Learn more about FTD

AFTD CEO
Susan Dickinson to Retire in May 2026

Read More View Job Posting

AFTD Board Leading Search for Successor

Thursday, November 6, 2025
3:00 p.m. ET

Alector Clinical Trial Results Townhall

Supporting FTD Care Partners with Individual Therapy:

HEALTHCARE PROFESSIONAL WEBINAR

Approaches and Key Considerations

CEC credit available for viewing the live webinar

Tuesday, November 18, 2025
12-1 p.m. EST

Read the Full Plan

2025-2028

Paving the Path Forward:

Strategic Plan

Diagnosis and Treatment

Quality Care and Support

Advocacy and Awareness

Infrastructure and Sustainability

Since research is expanding so rapidly, AFTD is pleased to offer two ways for you to stay informed based on your level of scientific understanding.

Are you interested in staying up to date on FTD research?

Written for People on the FTD Journey Written for Researchers & Professionals

News & Events

Dawn Kirby Interviewed on Podcast - FBLI

AFTD Ambassador and “Protective Mama Bear” Dawn Kirby Interviewed on Podcast

Dawn Kirby’s daughter Kara was diagnosed with FTD at age 29. In a recent episode of the podcast For Their Thoughts, she shared her experience as a mother fighting for…

FTD Science Digest – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable

This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for…

Banner: Meet the Researcher - Celebrating Professionals Committed to FTD Research - Indira Garcia-Cordero, PhD

Meet the Researcher: Indira García-Cordero, PhD

“Over the years, I have had the privilege of meeting and working with people living with FTD and their families. Their strength and resilience have inspired me and motivated me…

Graphic Text: Tips & Advice: New Reccommendation: Expanding Genetic Counseling and Testing for People Diagnosed with FTD | Background: A woman and her mother discuss matters with their doctor in an office

New Recommendation: Expanding Genetic Counseling and Testing for People Diagnosed with FTD

The FTD genetic research landscape is evolving at an unprecedented pace. Although most FTD cases do not have a hereditary component, numerous clinical trials are now targeting gene-specific treatments, areas…

How FTD Revealed Deb Jobe's Hidden Artist - FBLI

A Rose with Pink Petals: How FTD Revealed Deb Jobe’s Hidden Artist

Deb Jobe, co-chair of the AFTD Persons with FTD Advisory Council, was featured in the journal Brain & Life for the blooming of her artistic ability alongside FTD symptoms. Jobe…

Graphic Text: Tips & Advice: When "I'm Find" Isn't Fine - Understanding Anosognosia in FTD | Background: A woman has a discussion with her elderly mother

When “I’m Fine” Isn’t Fine – Understanding Anosognosia in FTD

“I’m not going back to that doctor. I don’t have FTD. I’m fine.” This type of response from someone who has just received an FTD diagnosis can seem like denial,…

Pave the Path Forward to End FTD with a Year-End Gift

Since AFTD was founded in 2002 by Helen-Ann Comstock with her personal gift of $1,000, our work has been powered by the dedication of volunteers, donors, and all those we…

Alector Therapeutics Announces Results From Their Phase 3 Clinical Trial Evaluating Latozinemab

On October 21, 2025, Alector Therapeutics announced results from their Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) for people with FTD caused by variants in the progranulin (GRN gene).…

SEE CALENDAR VIEW

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News & Events

Have Questions?